



# Regulatory Roundup

---

Weekly Webinar for Long-Term Care Professionals

---

 [IHCA.org/regulatory-roundup](https://ihca.org/regulatory-roundup)

## PRESENTERS

**Lori Davenport**

Indiana Health Care Association

**Team Members from**

Indiana Department of Health

---

October 12, 2023



# Today's Agenda

- Upcoming Education – Katie Niehoff
  - Oct 23: [Steering Survey Success](#) (webinar)
  - Nov 2: [Certified Dementia Practitioner course](#) (virtual)
  - Nov 8: [Bronze Quality Awards Workshop](#) (webinar) ***IHCA/INCAL Members Only***
  - Nov 15-16: [SNF DON Workshop](#) (in-person)
  - Nov 30: [Managed Care Workshop](#) (in-person) ***IHCA/INCAL Members Only***
- IHCA Membership Survey – Katie Quigley
- Novavax Updated COVID vaccine and ATP Equipment request for survey completion – Dr. Vuppalanchi
- Misc. – Lori Davenport



IHCA/INCAL PRESENTS

# Director of Nursing WORKSHOP

**November 15-16, 2023**


---

Renaissance Indianapolis North Hotel, Carmel, IN 46032

---



**BIT.LY/DONWORKSHOP**



# IHCA/INCAL Members Only Event



IHCA/INCAL PRESENTS

## MANAGED CARE WORKSHOP

November 30, 2023

---

Renaissance Indianapolis North Hotel, Carmel, IN 46032

---



[BIT.LY/MANAGEDCARETRAINING](https://bit.ly/managedcaretraining)

# Antibiotics Awareness Week Webinar Series



The Indiana Department of Health's Healthcare Associated Infections and Antimicrobial Resistance Team is hosting a free webinar series on Nov. 13, 15 and 17, prior to [U.S. Antibiotic Awareness Week](#). Each webinar is scheduled to occur from 1:00 PM to 3:00 PM.

Topics will include antimicrobial stewardship programs, antibiograms, susceptibility results and multidrug resistant organisms, and will be presented by field experts.

**Scan the QR code at right** to register for the webinar series. Registration for the Microsoft Teams virtual event will be open until Nov. 13.



## Questions?

Please visit the IDOH webpage [here](#) or contact **Dhivya Selvaraj** at 812-287-3595 or [DSelvaraj@health.in.gov](mailto:DSelvaraj@health.in.gov).



## Schedule of Events

### Nov. 13

- Core Elements of Antimicrobial Stewardship Programs in both Long Term and Acute Care Settings

### Nov. 15

- Antibiogram overview
- Reading Understanding and Using Antimicrobial Susceptibility Results
- Data dashboards
- Indiana AWARE

### Nov. 17

- Health Equity and Antimicrobial Stewardship
- Carbapenem-resistant Enterobacterales
- *Candida auris*

Note: Topics are subject to change up until the date of listed event.

# HELP US SERVE YOU BETTER

We invite IHCA/INCAL's members to participate in a short survey



SCAN HERE

★ ★ ★ EXCLUSIVE OPPORTUNITY ★ ★ ★

TAKE THE SURVEY FOR YOUR CHANCE TO WIN A  
FREE REGISTRATION TO 2024 IHCA/INCAL  
CONVENTION & EXPO (VALUED AT \$325)

[BIT.LY/IHCASURVEY](https://bit.ly/ihcassurvey)

DEADLINE: OCTOBER 20





**Indiana**  
**Department**  
**of**  
**Health**

# PUBLIC HEALTH UPDATES

**SHIREESHA VUPPALANCHI, M.D**  
MEDICAL DIRECTOR

10/12/2023

OUR MISSION:

To promote, protect, and improve the health and safety of all Hoosiers.

OUR VISION:

Every Hoosier reaches optimal health regardless of where they live, learn, work, or play.





# ATP equipment request survey

---

<https://redcap.isdh.in.gov/surveys/?s=49TCNRK7JA48WHTM>

Deadline: Oct. 20

# Updated COVID-19 vaccines

---

- The 2023–2024 formulation for all COVID-19 vaccines licensed or authorized in the United States (Moderna, Novavax, and Pfizer-BioNTech) has been updated to a monovalent vaccine based on the Omicron XBB.1.5 sublineage of SARS-CoV-2.
- The Original monovalent and bivalent (Original and Omicron BA.4/BA.5) formulations should no longer be used.
- There is no preferential recommendation for the use of any one COVID-19 vaccine over another when more than one recommended and age-appropriate vaccine is available.

# Novavax COVID-19 Vaccine

---

## Summary of recent changes (last updated October 6, 2023):

- The updated 2023–2024 formulation of Novavax COVID-19 Vaccine is recommended for people ages 12 years and older as follows:
  - Initial vaccination: 2 doses of updated (2023–2024 Formula) Novavax COVID-19 Vaccine
  - Previously vaccinated with any Original monovalent or bivalent COVID-19 vaccine (Moderna, Novavax, Pfizer-BioNTech, Janssen): 1 dose of updated (2023–2024 Formula) Novavax Vaccine
- People who are moderately or severely immunocompromised may receive 1 or more additional updated (2023–2024 Formula) Novavax vaccine doses.
- People ages 12 years and older have the option of receiving either the updated (2023–2024 Formula) mRNA (Moderna, Pfizer-BioNTech) or updated (2023–2024 Formula) Novavax vaccine.

Ages 12 years and older

# General population without immunocompromising conditions

COVID-19 vaccination history prior to updated (2023–2024 Formula) vaccine*	Updated (2023–2024 Formula) vaccine	Number of updated (2023–2024 Formula) doses indicated	Dosage (mL/ug)	Vaccine vial cap and label colors <sup>§</sup>	Interval between doses
Unvaccinated	Moderna	1	0.5 mL/50 ug	Dark blue cap; blue label	—
	OR				
	Novavax	2	0.5 mL/5 ug rS protein and 50 ug Matrix-M adjuvant	Blue cap; blue label	Dose 1 and Dose 2: 3–8 weeks <sup>†</sup>
	OR				
	Pfizer-BioNTech	1	0.3 mL/30 ug	Gray cap; gray label	—
1 or more doses any mRNA; 1 or more doses Novavax or Janssen, including in combination with any Original monovalent or bivalent COVID-19 vaccine doses	Moderna	1	0.5 mL/50 ug	Dark blue cap; blue label	At least 8 weeks after last dose
	OR				
	Novavax	1	0.5 mL/5 ug rS protein and 50 ug Matrix-M adjuvant	Blue cap; blue label	At least 8 weeks after last dose
	OR				
	Pfizer-BioNTech	1	0.3 mL/30 ug	Gray cap; gray label	At least 8 weeks after last dose

[Clinical Guidance for COVID-19 Vaccination | CDC](#)



# Moderate to Severely Immunocompromised

Ages 12 years and older\*

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#table-02>

COVID-19 vaccination history prior to updated (2023–2024 Formula) vaccine†	Updated (2023–2024 Formula) vaccine	Number of updated (2023–2024 Formula) doses indicated‡	Dosage (mL/ug)	Vaccine vial cap and label colors§	Interval between doses
Unvaccinated	Moderna	3	0.5 mL/50 ug	Dark blue cap; blue label	Dose 1 and Dose 2: 4 weeks Dose 2 and Dose 3: At least 4 weeks
	OR				
	Novavax	2	0.5 mL/5 ug rS protein and 50 ug Matrix-M adjuvant	Blue cap; blue label	Dose 1 and Dose 2: 3 weeks
	OR				
	Pfizer-BioNTech	3	0.3 mL/30 ug	Gray cap; gray label	Dose 1 and Dose 2: 3 weeks Dose 2 and Dose 3: At least 4 weeks

# Moderate to Severely Immunocompromised

Ages 12 years and older\*

COVID-19 vaccination history prior to updated (2023–2024 Formula) vaccine <sup>†</sup>	Updated (2023–2024 Formula) vaccine	Number of updated (2023–2024 Formula) doses indicated <sup>‡</sup>	Dosage (mL/ug)	Vaccine vial cap and label colors <sup>§</sup>	Interval between doses
1 dose any Moderna	Moderna	2	0.5 mL/50 ug	Dark blue cap; blue label	Dose 1: 4 weeks after last dose Dose 1 and Dose 2: At least 4 weeks
2 doses any Moderna	Moderna	1	0.5 mL/50 ug	Dark blue cap; blue label	At least 4 weeks after last dose
1 dose any Pfizer-BioNTech	Pfizer-BioNTech	2	0.3 mL/30 ug	Gray cap; gray label	Dose 1: 3 weeks after last dose Dose 1 and Dose 2: At least 4 weeks
2 doses any Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/30 ug	Gray cap; gray label	At least 4 weeks after last dose

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#table-02>

Ages 12 years and older\*

# Moderate to Severely Immunocompromised

<https://www.cdc.gov/vaccines/clinical-considerations/interim-considerations-us.html#table-02>




COVID-19 vaccination history prior to updated (2023–2024 Formula) vaccine <sup>†</sup>	Updated (2023–2024 Formula) vaccine	Number of updated (2023–2024 Formula) doses indicated <sup>‡</sup>	Dosage (mL/ug)	Vaccine vial cap and label colors <sup>§</sup>	Interval between doses
3 or more doses any mRNA vaccine	Moderna	1	0.5 mL/50 ug	Dark blue cap; blue label	At least 8 weeks after last dose
	OR				
	Novavax	1	0.5 mL/5 ug rS protein and 50 ug Matrix-M adjuvant	Blue cap; blue label	At least 8 weeks after last dose
	OR				
	Pfizer-BioNTech	1	0.3 mL/30 ug	Gray cap; gray label	At least 8 weeks after last dose
1 or more doses Novavax or Janssen, including in combination with any Original monovalent or bivalent COVID-19 vaccine doses	Moderna	1	0.5 mL/50 ug	Dark blue cap; blue label	At least 8 weeks after last dose
	OR				
	Novavax	1	0.5 mL/5 ug rS protein and 50 ug Matrix-M adjuvant	Blue cap; blue label	At least 8 weeks after last dose
	OR				
	Pfizer-BioNTech	1	0.3 mL/30 ug	Gray cap; gray label	At least 8 weeks after last dose

# RESP-NET

Surveillance through a network of acute care hospitals in select counties in 13 states. The surveillance platforms for COVID-19, Influenza, and RSV (known as COVID-NET, FluSurv-NET, and RSV-NET, respectively) cover more than 29 million people and include an estimated 8-10% of the U.S. population. CA, GA, IA, MD, MI, MN, NM, NY, OH, OR, TN

[RESP-NET Interactive Dashboard | CDC](#)





# COVID-19 data from CDC

## COVID-19 Update for the United States

### Early Indicators

#### Test Positivity >

% Test Positivity

10.9%

(September 24 to September 30, 2023)

Trend in % Test Positivity

**-1.2%** in most recent week



Aug 12, 2023

Sep 30, 2023

#### Emergency Department Visits >

% Diagnosed as COVID-19

1.6%

(September 24 to September 30, 2023)

Trend in % Emergency Department Visits

**-14.5%** in most recent week



Aug 12, 2023

Sep 30, 2023

### Severity Indicators

#### Hospitalizations >

Hospital Admissions

18,139

(September 24 to September 30, 2023)

Trend in Hospital Admissions

**-6%** in most recent week



Aug 12, 2023

Sep 30, 2023

#### Deaths >

% of All Deaths in U.S. Due to COVID-19

2.7%

(September 24 to September 30, 2023)

Trend in % COVID-19 Deaths

**+3.8%** in most recent week



Aug 12, 2023

Sep 30, 2023

# Indiana COVID-19 data



## Indiana COVID-19 Home Dashboard

Below results are as of 9/26/2023, 11:59 PM. Dashboard updates by 5 p.m. on Wednesdays.

7-Day Average  
COVID-19 Counts  
*(Total Counts in Italics)*

COVID-19 Hospital  
Admissions  
**42 (↓10)**  
*163,127 Total Count*



Emergency Department  
Visits for  
COVID-Like Illness  
**289 (↓24)**  
*515,681 Total Count*

COVID-19 Trends from 2/26/2020 to  
9/27/2023


■ COVID-19 Hospital Admissions ■ Emergency Department Visits  
for COVID-Like Illness

Event Date  
(filters timeseries only)

2/26/2020 9/27/2023



# Indiana COVID-19 data



**COVID-19 Deaths**  
**2 (↓1)**  
*25,465 Total Count*  
*1,271 Probable Deaths*

**COVID-19 Cases**  
**373 (↓36)**  
*2,110,709 Total Count*

**SARS-CoV-2 Wastewater Concentration**  
**0.00738 (↓0.00070)**  
*1,647,712 Total Population Served*

All numbers are provisional and reflect only those reported to IDOH. Numbers should not be characterized as a comprehensive total and may change as more data is reported.








# Fall respiratory season

[https://www.in.gov/health/files/23\\_FALL-immunizations.pdf](https://www.in.gov/health/files/23_FALL-immunizations.pdf)

## WHAT YOU NEED TO KNOW ABOUT FALL VACCINES 2023

Immunizations have been shown to lower risk of severe disease. Speak to your health care provider about the best timing for you.

Vaccine	Who	What	When
 FLU	People 6 months and older, adults over 65 may choose to get higher dose	One dose that targets multiple flu strains	September and October
 COVID	Everyone aged 6 years and older should get 1 updated Pfizer-BioNTech or Moderna COVID-19 vaccine to be up to date.	Booster vaccine targeting newer variants	September and October
 RSV	Adults over 60	One dose vaccine	September and October
 RSV	Pregnant people at 32-36 weeks	One dose vaccine	September and October
 RSV	Infants under 8 months	Monoclonal antibody shot	For babies starting this Fall until Spring, talk to your pediatrician

# Questions?

## CONTACT:

**Shireesha Vuppalanchi, MD**

Medical Director

Indiana Department of Health

[svuppalanchi@health.in.gov](mailto:svuppalanchi@health.in.gov)



# Brief Interview for Mental Status Video



CMS developed a [brief interview for mental status](#) video (03:23) to help you determine:

- When to stop the interview
- How to code the remaining items

Contact the [PAC Training Mailbox](#) with questions or feedback.

# User Friendly Way to Check COVID-19 Test Expiration Dates

- Check the expiration date for at home COVID-19 test
- <https://covid19.ncdhhs.gov/NewDate>
- The FDA may have extended the expiration date of your at-home COVID-19 test. Find out if your tests have been extended.
- English and Spanish version

# Bed Management – COVID-19

- Medicaid bed – individual resident is COVID-19 positive
- Roommate is also in a Medicaid bed and is COVID-19 negative and symptom free but is high risk
- Roommate refuses to move
- There is not another available Medicaid bed for to move the COVID-19 positive person into.
  - What is expected ? Regulatory – Financial – Best practice  
ISDH answer – Allow for resident choice – if the resident will not move and the risks and benefits discussed in a way that they understand, they may stay. Document!



# Staffing Question



- Is it true? A provider will receive an automatic citation during a survey if they have a 1-star staffing.
  - No, it is not automatic
  - It is something for the survey team to investigate

# Question - Dietary Manager

- In 2022, the IDOH rescinded that a Certified Manager certification is required for Directors of Dining Services; is a Certified Dietary Manager required to be on staff at the facility in any capacity?
- **IDOH feels it is required to have a CDM or one of the following:**

# Continued



§483.60(a)(2) If a qualified dietitian or other clinically qualified nutrition professional is not employed full-time, the facility must designate a person to serve as the director of food and nutrition services.

- (i) The director of food and nutrition services must at a minimum meet one of the following qualification –
  - A) Certified dietary manager; or
  - B) A certified food service manager; or
  - C) Has similar national certification for food service management and safety from a notional certifying body; or
  - D) Has an associate's or higher degree in food service management or in hospitality, if the course study includes food service or restaurant management, from an accredited institution of higher learning;

# Continued



E) Has 2 or more years of experience in the position of director of food and nutrition services in a nursing facility setting and has completed a course of study in food safety and management, by no later than October 1, 2023, that includes topics integral to managing dietary operations including, but not limited to, foodborne illness, sanitation procedures, and food purchasing/receiving;

And (ii) In states that have established standards for food service managers or dietary managers, meets State requirements for food service managers or dietary managers, and (iii) Receives frequently scheduled consultations from a qualified dietitian or other clinically qualified nutrition professional.

# Baseline Temperatures

- During Myers and Stauffer Audit, the RN Reviewer stated that baseline temperatures are required annually. Is there a regulation that requires establishing a new baseline temperature annually?
- Not a state or federal requirement
- RAI Manual - Fever: Fever is defined as a temperature 2.4 degrees F higher than baseline. The resident's baseline temperature should be established prior to the Assessment Reference Date.
- Fever assessment prior to establishing base line temperature: A temperature of 100.4 degrees F (38 degrees C) on admission (i.e., prior to the establishment of the baseline temperature) would be considered a fever.
- RAI Manual
  - J1550 Problem Conditions – Reference – recommend reviewing

# Question – Fans

Now that the pandemic is over – and kitchen are hot – providers want to carefully use fans again in the kitchen.

Fans would be cleaned on a regular schedule.

Fans can be used. Clean and not blowing over food.

# Submit Comments to CMS

- Proposed Minimum Staffing Rule
- Comment period ends – November 6, 2023

# Vaccines



- Provide the flu vaccine when you get access
- Let your residents know what vaccines they are eligible for
- Let your staff know what vaccines they are eligible for
- Informed consent or declination – document!



# IDOH Leadership Conference

- Biltwell Event Center
- Building a Culture of Care – Preventing Abuse in Nursing Homes
- October 17 – 8:30 am
- **Register here:** <https://host.regform.com/the-indiana-healthcare-leadership-conference/>
- Next weeks Roundup will be canceled

# Next Regulatory Roundup

October 26, 2023 – 12:00pm EST

# Q&A



**Indiana**  
Department  
of  
**Health**

## Long-term Care NEWSLETTER

LTC Newsletter 2023-19  
Sept. 14, 2023

---

### LTC Update:

- Adenosine Triphosphate (ATP) Luminometers Available for Facility Use
- Updated COVID-19 Vaccine

### Adenosine Triphosphate (ATP) Luminometers Available for Facility Use

Please complete a short survey if you would like to receive ATP equipment for use in your long-term care facility. Please complete the [survey](#) by Oct. 15, to ensure you are on the distribution list.

Healthcare associated infections (HAIs) are a major public health issue. Proper environmental cleaning and disinfection in healthcare settings is crucial for reducing the risk of HAIs. Adenosine triphosphate (ATP) is the energy molecule found in all living cells and can be measured as a useful marker for bioburden. Evaluating cleaning practices with an ATP luminometer can help identify gaps of disinfection processes.

Indiana Department of Health (IDOH) is purchasing ATP luminometers and swabs (together called ATP equipment) for long-term care facilities using funds provided by the Centers for Disease Control and Prevention. The long-term care (LTC) **facilities that would like to receive the ATP equipment must fill out the [survey](#) by Oct. 15**. The ATP equipment will be delivered directly to the facility.

Please gather the following information to answer the [survey](#):

- Full name of the facility
- Exact shipping address
- Contact person's name, phone number, and email address

- Number of beds in the facility
- Number of ATP equipment requested
  - It is recommended to request for one unit if the facility has fewer than 100 skilled nursing beds and two units if more 100 skilled nursing beds.
  - Facilities with high infection control needs such as MDRO unit/ vent unit/ high MDRO infections may request for two units even if they have fewer than 100 beds.
- Each facility must complete survey only once. If more than one survey is received, only the latest submission will be used in final planning.

Please note the following important things:

- Follow the instructions provided by the manufacturer for use of ATP equipment.
- Use the swabs to evaluate the cleanliness after environmental cleaning.
- Store the swabs at appropriate temperatures per the manufacturer guidance.
- Once the packet of swabs is open, finish using the swabs within the time frames recommended by the manufacturer.
- Further education on how and where to use the ATP equipment will be provided at a later date by the manufacturer and/or IDOH's HAI-AR (Healthcare Associated Infections-Antibiotic Resistance) team as needed.

Please email questions to Dr. Shireesha Vuppalanchi at [svuppalanchi@health.in.gov](mailto:svuppalanchi@health.in.gov).

## Updated COVID-19 Vaccine

The Centers for Disease Control and Prevention (CDC) recommends everyone 6 months and older get an [updated COVID-19 vaccine](#) to protect against the potentially serious outcomes of COVID-19 illness this fall and winter.

LTC facilities should procure the updated COVID-19 vaccine through their pharmacy partnerships and offer it to all the eligible residents. Please begin ordering vaccine immediately as updated COVID-19 vaccines from Pfizer-BioNTech and Moderna will be available later this week.

Vaccination remains the best protection against COVID-19-related hospitalization and death. Vaccination also reduces the chance of suffering the effects of Long COVID, which can develop during or following acute infection and last for an extended duration. The CDC's recommendation is that anyone who has not received a COVID-19 vaccine in the past 2 months get an updated COVID-19 vaccine. Please review the CDC's [Interim Clinical Considerations for use of COVID-19 Vaccines](#) for detailed clinical recommendations in the coming days.

Preliminary COVID-19 vaccine recommendations [presented at the ACIP meeting](#) (slide 130) include:

- Everyone 5 years of age and older is recommended to receive 1 dose of an updated mRNA vaccine (Moderna or Pfizer-BioNTech), regardless of prior vaccination history
- People who are moderately or severely immunocompromised should complete a 3-dose initial series with at least one dose of the updated COVID-19 vaccine, and may receive additional updated vaccine doses

The CDC's recommendation follows the U.S. Food and Drug Administration's vaccine [approval](#) earlier this week. Please note that the updated mRNA vaccines are each approved for individuals 12 years of age and older.